They found that an FDA approved drug for non-small cell lung cancer called ceritinib has anti-cancer activity against previously unknown targets. Their results were published today in the
Top-line data, based on the 16-week primary endpoint, is anticipated early in the first quarter of 2018. Subjects were enrolled in 30 renal centres across the USA. A
The milestone is due to the successful completion of a screening campaign using Evotec's induced pluripotent stem cell ("iPSC")-based screening platform. This milestone has been achieved under an
These funds will enable clinical advancement of PAN-90806, a small molecule anti-vascular endothelial growth factor (anti-VEGF) eye drop for the treatment of neovascular eye diseases. The additional financing,
Synthon’s three-times-a-week glatiramer acetate is a therapeutically equivalent version of the originator medicine Copaxone®* 40mg. Synthon received regulatory clearance in all 27 EU/EEA member states involved in the
The company raised an initial $23.1 million in June 2016. The extension of the Series C supports Visterra’s focus on its two lead product candidates, VIS410 and VIS649,
This landmark research is a collaboration between Anthem, Inc., its outcomes research subsidiary, HealthCore, Inc. and Boehringer Ingelheim, a pharmaceutical company with a long history of leadership in
Under the terms of the agreement, Ligand will pay Crystal shareholders $25 million in cash at closing, up to an additional $10.5 million of success-based milestones, and revenue
The over-subscribed round brings the company's total capital raised to more than $80 million. Recursion augments traditional drug discovery approaches, most prominently phenotypic screening, with artificial intelligence (AI).
The latest agreement with Bayer extends their access to X-Chem’s DEX™ technology by including the synthesis of custom Bayer DNA-Encoded Libraries and expanding the number of potential programs.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.